Sign In
Buy IMMP
$0.377
+0.0030 (+0.80%)
At Close: Jun 22, 2026
Immutep (IMMP) Receives a Buy from Maxim Group
02:46pm, Thursday, 30'th Apr 2020
In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to Immutep (IMMP), with a price target of $2.00. The company's shares
Immutep (IMMP) Receives a Buy from Maxim Group
02:46pm, Thursday, 30'th Apr 2020
In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to Immutep (IMMP – Research Report),
SYDNEY, Australia, April 30, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new data are scheduled to be presented in two.
Immutep Reports Positive Phase II TACTI-002 Data
12:00pm, Tuesday, 28'th Apr 2020
Increasing benefit reported from patients with first line Non-Small Cell Lung Cancer (NSCLC): º Improving Overall Response Rate (ORR) of 53% (earlier data indicated 47%) º.
The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight
08:37pm, Sunday, 26'th Apr 2020
The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market. Two FDA approvals came through this week, with Immunomedics, Inc.'s
Immutep reports enrollment completed for INSIGHT-004 study IMMP;MKGAY;PFE
07:55am, Thursday, 23'rd Apr 2020
Immutep reports enrollment completed for INSIGHT-004 study IMMP MKGAY PFE
Market Sentiment Around Loss-Making Immutep Limited (ASX:IMM)
12:28am, Thursday, 23'rd Apr 2020
Immutep Limited's (ASX:IMM): Immutep Limited, a biotechnology company, engages in the research, development, and...
Enrollment completed for the INSIGHT-004 Study
12:17am, Wednesday, 22'nd Apr 2020
SYDNEY, Australia, April 22, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments.
Immutep Advances Cell Line Development for IMP761
01:35am, Thursday, 16'th Apr 2020
SYDNEY, Australia, April 16, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce that Batavia Biosciences, its manufacturing.
MT, SSL among premarket losers
01:16pm, Wednesday, 15'th Apr 2020
Obalon Therapeutics (NASDAQ:OBLN) -25%.NeuroMetrix (NASDAQ:NURO) -16%.Cocrystal Pharma (NASDAQ:COCP) -14%.Covanta Holding (NYSE:CVA) -12% on dividend cut and guidance pull.Independence Contract Dri
Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020
04:06am, Tuesday, 14'th Apr 2020
SYDNEY, Australia, April 14, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments.
Immutep’s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer
12:00pm, Wednesday, 08'th Apr 2020
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to inform that EOC Pharma (“EOC”) and Immutep jointly discussed the current AIPAC results and confirmed plan
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 25.) * Ra Pharmaceuticals Inc (NASDAQ: RARX)Down In The
The Daily Biotech Pulse: T2 Biosystems Licenses COVID-19 Test, Immuron CEO Steps Down
11:29am, Wednesday, 25'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 24) * BELLUS Health Inc (NASDAQ: BLU) * Global Cord
Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020
01:35am, Wednesday, 25'th Mar 2020
Progression Free Survival (PFS) Hazard Ratio improvement for eftilagimod alpha (efti) group versus placebo at the 6-month landmarkIncreased Overall Response Rate (ORR) of 48.3%.
